FI944730A0 - CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja - Google Patents

CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja

Info

Publication number
FI944730A0
FI944730A0 FI944730A FI944730A FI944730A0 FI 944730 A0 FI944730 A0 FI 944730A0 FI 944730 A FI944730 A FI 944730A FI 944730 A FI944730 A FI 944730A FI 944730 A0 FI944730 A0 FI 944730A0
Authority
FI
Finland
Prior art keywords
surface antigens
related surface
immunotoxins against
immunotoxins
antigens
Prior art date
Application number
FI944730A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI944730A7 (fi
FI944730L (fi
Inventor
Michael G Rosenblum
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of FI944730A7 publication Critical patent/FI944730A7/fi
Publication of FI944730L publication Critical patent/FI944730L/fi
Publication of FI944730A0 publication Critical patent/FI944730A0/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI944730A 1992-04-10 1993-04-08 CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja FI944730A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86669392A 1992-04-10 1992-04-10
PCT/US1993/003284 WO1993020848A1 (en) 1992-04-10 1993-04-08 Immunotoxins directed against cd33 related surface antigens

Publications (3)

Publication Number Publication Date
FI944730A7 FI944730A7 (fi) 1994-10-07
FI944730L FI944730L (fi) 1994-10-07
FI944730A0 true FI944730A0 (fi) 1994-10-07

Family

ID=25348185

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944730A FI944730A0 (fi) 1992-04-10 1993-04-08 CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja

Country Status (13)

Country Link
EP (2) EP1656950A1 (enExample)
JP (1) JP3949158B2 (enExample)
KR (1) KR950700760A (enExample)
CN (1) CN1056084C (enExample)
AU (1) AU675226B2 (enExample)
CA (1) CA2133838C (enExample)
FI (1) FI944730A0 (enExample)
IL (1) IL105344A (enExample)
NO (1) NO314686B1 (enExample)
NZ (1) NZ252799A (enExample)
RU (1) RU2127122C1 (enExample)
WO (1) WO1993020848A1 (enExample)
ZA (1) ZA932523B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
PL403488A1 (pl) * 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
TW200726776A (en) * 2005-07-29 2007-07-16 Friedrich Alexander University Of Erlangen Nuremberg CD33-specific single-chain immunotoxin and methods of use
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
CN110662765B (zh) 2017-08-03 2023-09-29 艾利妥 抗cd33抗体及其使用方法
AU2019331018A1 (en) 2018-08-31 2021-03-11 Alector Llc Anti-cd33 antibodies and methods of use thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
ES2152216T3 (es) * 1989-12-14 2001-02-01 Sloan Kettering Inst Cancer Usos terapeuticos de la region hipervariable del anticuerpo monoclonal m195 y constructos de la misma.

Also Published As

Publication number Publication date
FI944730A7 (fi) 1994-10-07
KR950700760A (ko) 1995-02-20
CN1078401A (zh) 1993-11-17
AU4280193A (en) 1993-11-18
JP3949158B2 (ja) 2007-07-25
NO943776L (no) 1994-11-25
RU2127122C1 (ru) 1999-03-10
FI944730L (fi) 1994-10-07
CN1056084C (zh) 2000-09-06
IL105344A (en) 2000-06-29
CA2133838A1 (en) 1993-10-28
WO1993020848A1 (en) 1993-10-28
IL105344A0 (en) 1993-08-18
AU675226B2 (en) 1997-01-30
NO943776D0 (no) 1994-10-07
JPH08501059A (ja) 1996-02-06
CA2133838C (en) 2003-07-29
KR100291377B1 (enExample) 2001-09-17
EP0634938A1 (en) 1995-01-25
NO314686B1 (no) 2003-05-05
EP1656950A1 (en) 2006-05-17
EP0634938A4 (en) 1998-06-03
NZ252799A (en) 1996-10-28
ZA932523B (en) 1994-10-08

Similar Documents

Publication Publication Date Title
FI931437A0 (fi) Preparat mot eksem
DE69323565D1 (de) Verbindung
DE69332090D1 (de) Holographievorrichtung
FI924079L (fi) Mot frysning skyddande transportenheter
FI931284L (fi) Foerfarande foer foerbaettring av belaeggningars resistens mot vattenblekning
KR930025206U (ko) 표면 파스너
DE69323336D1 (de) Ultraschallgetriebener Motor
FI944730A0 (fi) CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja
FI934145L (fi) Omformade monoklonala antikroppar mot en immunoglobulinisotyp
DE59306006D1 (de) Oberflächenresistente Bauteile
FI930976A0 (fi) Mot tumoer riktande foerfarande och aemne
DE69303318D1 (de) Geradliniger seitlicher Anschlag
DE59304631D1 (de) Formmasse
DE69307212D1 (de) Ultraschallmotor
FI961392A0 (fi) Suojaavia antigeeneja loisia vastaan
ITMI931955A0 (it) Pellicola di copertura termosaldabile
DE59308065D1 (de) Verpackung
KR930020951U (ko) 여행용 코펠
ATA193592A (de) Verpackung
KR930021284U (ko) 유지장판지
KR940001194U (ko) 마루판
KR950008148U (ko) 용접면
SE9202239L (sv) Emanuelle II
BR9202399A (pt) Jifo ii
SE9201624L (sv) Förpackning

Legal Events

Date Code Title Description
FD Application lapsed